07-20-2008, 09:44 PM
|
 |
Lecturer
|
� |
Join Date: Apr 2006
Location: Propecia, CA
Posts: 1,851
|
|
Curcumin vs. Pancreatic Cancer
Quote:
In a phase II study involving 21 patients with advanced pancreatic cancer, oral supplementation with 8 g/d curcumin was found to be well-tolerated, and in some patients, was found to have biological activity.
The patients in this study received curcumin daily until disease progression, with restaging every 2 months. Results found that after taking curcumin, circulating levels were detectable at low steady-state levels, suggestive of poor bioavailability.
Important to note, 2 patients were found to show biological activity of curcumin. While taking curcumin, one patient was found to maintain a stable disease state for more than 18 months, and another patient was found to have a brief, but marked, significant regression of the tumor (73%), along with significant increases in (from 4- to 35-fold increases) serum cytokine levels.
In addition, curcumin was found to down-regulate expression of NF-kappaB, cyclooxygenase-2, and phosphorylated signal transducer and activator of transcription 3 in peripheral blood mononuclear cells from patients for whom baseline levels were higher than normal healthy volunteers.
While plasma curcumin levels varied greatly between subjects, they peaked at 22 to 41 ng/mL and remained relatively constant over the first 4 weeks. No toxicities were found.
In light of the fact that there are currently only 2 pharmacological drugs approved by the FDA (in the U.S.) for the treatment of patients with advanced pancreatic cancer, and both of those drugs (gemcitabine and erlotinib) are only effective in less than 10% of patients, the results of this study are promising, offering hope that curcumin may be a potentially effective therapy for the treatment of patients with advanced pancreatic cancer. Additional research is warranted.
|
https://www.vitasearch.com/get-clp-summary/37548
|
Linear Mode
